Skip to main content
. Author manuscript; available in PMC: 2023 Sep 8.
Published in final edited form as: Sci Transl Med. 2023 Feb 8;15(682):eabn5649. doi: 10.1126/scitranslmed.abn5649

Fig. 5. D2C7+αCD40 therapy prevents CD8+ T cell exhaustion in gliomas.

Fig. 5.

CT-VIII (A, C, E) or GL-VIII (B, D, F) tumors were treated from days 6–9 after implantation by CED with Ctrl, D2C7, αCD40, and D+C therapies (n=4/group). Tumor hemispheres harvested 6-d post treatment were analyzed by flow cytometry. Data are mean ± SEM. (A-B) Frequencies of CD8+ T cells with central memory (Tcm: CD3+CD8+CD62L+CD44+) or effector memory (Tem: CD3+CD8+CD62L−CD44+) phenotype are presented. (C-D) Frequencies of CD8+ Tem cells expressing PD-1 only or multiple exhaustion markers (PD-1/TIGIT/Tim-3/Lag-3) are presented. (E-F) Frequencies of CD8+ Tem cells classified into specific exhaustion subsets based on Ly108+ and CD69+ expression are presented. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.